Zhongjie Fu1,2, Steven S Meng2, Samuel B Burnim2, Lois Eh Smith2, Amy Cy Lo1,3. 1. Department of Ophthalmology, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong. 2. Department of Ophthalmology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA. 3. Research Center of Heart, Brain, Hormone and Healthy Aging, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong.
Abstract
BACKGROUND: Retinopathy of prematurity is one of the leading causes of childhood blindness worldwide, with vessel growth cessation and vessel loss in phase I followed by neovascularization in phase II. Ischaemia contributes to its pathogenesis, and lutein protects against ischaemia-induced retinal damages. We aimed to investigate the effects of lutein on a murine model of oxygen-induced retinopathy. METHODS: Mouse pups were exposed to 75% oxygen for 5 days and returned to room air for another 5 days. Vascular obliteration, neovascularization and blood vessel leakage were examined. Immunohistochemistry for glial cells and microglia were performed. RESULTS: Compared with vehicle controls, mouse pups receiving lutein treatment displayed smaller central vaso-obliterated area and reduced blood vessel leakage. No significant difference in neovascular area was found between lutein and vehicle controls. Lutein promoted endothelial tip cell formation and maintained the astrocytic template in the avascular area in oxygen-induced retinopathy. No significant changes in Müller cell gliosis and microglial activation in the central avascular area were found in lutein-treated pups. CONCLUSIONS: Our observations indicated that lutein significantly promoted normal retinal vascular regrowth in the central avascular area, possibly through promoting endothelial tip cell formation and preserving astrocytic template. Our results indicated that lutein might be considered as a supplement for the treatment of proliferative retinopathy of prematurity because of its role in facilitating the revascularization of normal vasculature.
BACKGROUND:Retinopathy of prematurity is one of the leading causes of childhood blindness worldwide, with vessel growth cessation and vessel loss in phase I followed by neovascularization in phase II. Ischaemia contributes to its pathogenesis, and lutein protects against ischaemia-induced retinal damages. We aimed to investigate the effects of lutein on a murine model of oxygen-induced retinopathy. METHODS:Mouse pups were exposed to 75% oxygen for 5 days and returned to room air for another 5 days. Vascular obliteration, neovascularization and blood vessel leakage were examined. Immunohistochemistry for glial cells and microglia were performed. RESULTS: Compared with vehicle controls, mouse pups receiving lutein treatment displayed smaller central vaso-obliterated area and reduced blood vessel leakage. No significant difference in neovascular area was found between lutein and vehicle controls. Lutein promoted endothelial tip cell formation and maintained the astrocytic template in the avascular area in oxygen-induced retinopathy. No significant changes in Müller cell gliosis and microglial activation in the central avascular area were found in lutein-treated pups. CONCLUSIONS: Our observations indicated that lutein significantly promoted normal retinal vascular regrowth in the central avascular area, possibly through promoting endothelial tip cell formation and preserving astrocytic template. Our results indicated that lutein might be considered as a supplement for the treatment of proliferative retinopathy of prematurity because of its role in facilitating the revascularization of normal vasculature.
Authors: Matthew R Ritter; Eyal Banin; Stacey K Moreno; Edith Aguilar; Michael I Dorrell; Martin Friedlander Journal: J Clin Invest Date: 2006-11-16 Impact factor: 14.808
Authors: Jean-Sébastien Joyal; Ye Sun; Marin L Gantner; Zhuo Shao; Lucy P Evans; Nicholas Saba; Thomas Fredrick; Samuel Burnim; Jin Sung Kim; Gauri Patel; Aimee M Juan; Christian G Hurst; Colman J Hatton; Zhenghao Cui; Kerry A Pierce; Patrick Bherer; Edith Aguilar; Michael B Powner; Kristis Vevis; Michel Boisvert; Zhongjie Fu; Emile Levy; Marcus Fruttiger; Alan Packard; Flavio A Rezende; Bruno Maranda; Przemyslaw Sapieha; Jing Chen; Martin Friedlander; Clary B Clish; Lois E H Smith Journal: Nat Med Date: 2016-03-14 Impact factor: 53.440
Authors: Olajumoke Akinsulire; George Perides; Lorenzo Anez-Bustillos; Joanne Cluette-Brown; Arthur Nedder; Elizabeth Pollack; Pratibha Singh; Yan Liu; Lady Leidy Sanchez-Fernandez; Evelyn Obregon; Ece Bicak; Savanna Kiefer; William Yakah; Hilda V Gutierrez; Duy T Dao; Mustafa Vurma; Stefan Ehling; Douglas Gordon; Stephen DeMichele; Steven D Freedman; Camilia R Martin Journal: JPEN J Parenter Enteral Nutr Date: 2019-08-23 Impact factor: 4.016
Authors: Menaka C Thounaojam; Ravirajsinh N Jadeja; Shubhra Rajpurohit; Diana R Gutsaeva; Brian K Stansfield; Pamela M Martin; Manuela Bartoli Journal: J Clin Med Date: 2020-06-19 Impact factor: 4.241
Authors: Jessica K W Tsang; Susanne A Wolf; Inga M Pompoes; Antonia M Joussen; Wai Ching Lam; Di Yang; Amy C Y Lo Journal: Life (Basel) Date: 2021-01-22